Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion

Kazuyuki Kumagai1
Nobuchika Ogino2
Marie Fukami1
Mariko Furukawa1
1Kami-iida Daiichi General Hospital, Nagoya, Aichi, Japan; 2Shinjo Ophthalmologic Institute, Miyazaki, Japan

Purpose: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO).

Methods: This was a retrospective, interventional case series. Forty-one patients received a single 1.25 mg of IVB injection and followed by pro re nata protocol, 71 patients received a single intravitreal tPA, and 116 patients underwent phacovitrectomy with intraocular lens implantation.

Results: The baseline characteristics and follow-up periods were not significantly different among the three groups. The mean follow-up period was 55.5 months with a range of 12–160 months. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. The best-corrected visual acuity (BCVA) significantly improved in all groups at 1 year after the initial treatment (all, \(P<0.0001\)) and at the final visit (all, \(P<0.0001\)). The differences in the BCVA between the three groups were not significant at all times after the initial treatment.

Conclusion: The three groups led to similar long-term good visual outcomes. However, additional surgeries were performed in more than 30% of patients in the IVB and tPA groups.

Keywords: branch retinal vein occlusion, bevacizumab, tissue plasminogen activator, vitrectomy, macular edema

Introduction
Macular edema is a common cause of visual reduction in eyes with a branch retinal vein occlusion (BRVO). The main methods to treat BRVO include macular grid laser photocoagulation, intravitreal or posterior sub-tenon injection of triamcinolone acetate, intravitreal injection of tissue plasminogen activator (tPA), and vitrectomy.1–3

Recently, intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard treatment for this condition. However, there are several problems, for example, recurrence of macular edema which then requires repeat injections that can then increase the risk of complications. In addition, anti-VEGF agents are expensive, and repeated injections can become a financial burden on the patients.1,2,4–10

Several authors have reported on the effectiveness of intravitreal bevacizumab (IVB; Avastin),11–20 intravitreal tPA,21–25 and vitrectomy26–39 for the treatment of the macular edema associated with a BRVO. We have reported that these three different types of treatments had similar visual outcomes; however, one-third of eyes in the IVB and tPA groups required additional surgeries.36 A longer follow-up period...
was required to determine the final outcomes of these three treatments because vitrectomy was performed several years after the initial treatment in some eyes. We have extended the follow-up periods of the three groups especially for the IVB group. As a result, the mean follow-up period exceeded 50 months in all groups.

The purpose of this study was to determine the long-term outcomes of IVB or intravitreal tPA or vitrectomy on the macular edema associated with a BRVO.

Methods

Patients

We reviewed the medical records of the Kami-iida First General Hospital, the Shinjo Ophthalmologic Institute, and the Nishigaki Ophthalmologic Institute from January 2004 and March 2009. All patients who were diagnosed with a macular edema secondary to BRVO and had undergone either treatment, IVB (Avastin; Genentech Inc, San Francisco, CA), tPA (Monteplase, Eisai, Tokyo, Japan), or vitrectomy, were included.

The inclusion criteria were onset of <6 months, a progressive decrease in the visual acuity, and macular edema with symptoms and foveal hemorrhages. The exclusion criteria included eyes with vitreous hemorrhage, severe cataract, vitreomacular traction, presence of an epiretinal membrane, prior vitreoretinal surgery, prior macular grid laser photocoagulation, uncontrolled glaucoma, and other ocular diseases that could cause a reduction in vision.

All patients had signed an informed consent for the surgery, data collection, and the use of the data for research studies. The Ethics Committee of the hospitals approved the procedures used in this study, and the procedures conformed to the tenets of the Declaration of Helsinki.

All the patients had a complete ophthalmic examination including measurements of the best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, indirect ophthalmoscopy, fundus photography, fluorescein angiography, and foveal thickness accessed by optical coherence tomography (OCT 3; Carl Zeiss Meditec AG, Jena, Germany). Patients were examined preoperatively (baseline) and at 1 day, 1 week, 1, 2, 3, and 6 months after the treatment. The patients were examined every 3–6 months thereafter.

Surgical procedures

All surgeries were performed by one experienced surgeon (NO). Phacovitrectomy with intraocular lens implantation was performed on all phakic patients to avoid posttreatment cataract progression. Standard three-port pars plana vitrectomy was performed. A separation of the posterior hyaloid from the optic disk and posterior retina was performed when a posterior vitreous detachment was not present. All eyes had triamcinolone-assisted internal limiting membrane peeling. No eyes had intraocular or periocular triamcinolone injections.

Intravitreal injections of bevacizumab and tPA

The intravitreal injection was given through the pars plana with a 30-gauge needle under sterile conditions in the operating room. For the IVB group, each patient received a single intravitreal injection of 1.25 mg/0.05 mL bevacizumab and were followed with a pro re nata (PRN) regimen. Additional injections were received when a persistent or recurrent macular edema was documented by OCT. A recurrent macular edema was defined as foveal thickness increase by >30% after an initial decrease or a worsening of the BCVA by >0.2 logarithm of minimum angle resolution (logMAR) units after an initial improvement.

In the IVB group, all patients were classified into three types. In the “good response type,” the macular edema was resolved within three IVB injections, and the foveal thickness was maintained during follow-up periods. The second type was named the “vitrectomized type” because a recurrence or persistence of the macular edema was treated with vitrectomy. In the “persistent type,” the recurrence or persistence of macular edema remained during the entire follow-up period.

In the tPA group, each patient was given an intravitreal injection of 40,000 international units of tPA diluted with 0.25 mL of balanced salt solution and was instructed to maintain a supine position for 1–3 hours after the injection.

Statistical analyses

The decimal visual acuities were converted to the logMAR units for the statistical analyses. The paired t-tests were used to determine the significance of the differences in the BCVAs and foveal thicknesses, and chi-squared tests were used to determine the significance of the differences in the ratios of the BCVA and patients’ characteristics. The differences in the measured values among the groups were compared by ANOVA with post hoc comparisons tested by the Scheffe procedure. An improvement or worsening of the visual acuity was defined as changes that were greater or lesser than 0.2 logMAR units. A P<0.05 was accepted as statistically significant. Statistical analyses of data were carried out with the Statview 5.0 software (SAS Institute Inc., Cary, NC, USA).
Results

Two hundred thirty-eight eyes of 238 patients met our inclusion criteria. Ten patients were excluded from the statistical analyses because they had been followed for <12 months. Therefore, the analyses were performed on 228 eyes of 228 patients. Three groups were identified; 41 eyes had received IVB, 71 eyes had received intravitreal tPA, and 116 eyes had undergone vitrectomy.

The follow-up period was extended in 130 (57.0%) of the 228 patients. The mean extended follow-up period was 41 months with a range of 1–119 months. The mean follow-up period was 50 months for all groups. The follow-up period was at least 3 years in 155 eyes (68.0%) and at least 5 years in 70 eyes (30.7%).

The mean number of IVB during the follow-up period was 2.9 with a range of 1–7. For all eyes, nine eyes (22.0%) received one, eight eyes (19.5%) received two, eight eyes (19.5%) received three, 13 eyes (31.7%) received four, two eyes (4.9%) received five, and one eye (2.4%) received seven IVB injections.

In the IVB group, 15 eyes were placed in the good response type, 12 eyes in the vitrectomized type, and 14 eyes in the persistent type. The mean numbers of injections were 1.7, 3.9, and 3.2 for good response, vitrectomy, and persistently type, respectively.

The demographics and baseline characteristics of the patients are shown in Table 1. There were no significant differences among the groups except for the BCVA ≥20/40. The BCVA ≥20/40 was significantly higher in the tPA group than in the IVB and vitrectomy group; hence, there was no significance in the mean BCVA in logMAR. The patients with poorer visual acuity were found more frequently in the vitrectomy group.

A summary of the BCVAs and the foveal thicknesses at 12 months and at the final examination is presented in Table 2. There were no significant differences among the three groups except in the foveal thickness at 12 months and at the final visit. The mean thickness of the fovea was significantly thicker in the IVB and vitrectomy groups than in the tPA group at 12 months (P=0.0022 and P=0.017,

---

Table 1 Demographics and baseline characteristics

|                        | Bevacizumab (n=41) | tPA (n=71) | Vitrectomy (n=116) | P-value |
|------------------------|--------------------|-----------|--------------------|---------|
| Age, years, mean ± SD  | 66.0±12.2          | 66.4±10.4 | 66.0±10.5          | 0.97    |
| Female, n (%)          | 19 (46.3)          | 32 (45.1) | 62 (55.2)          | 0.34    |
| Lens status, n (%)     |                    |           |                    |         |
| Phakic                 | 39 (95.1)          | 63 (88.7) | 111 (95.7)         |         |
| Pseudophakic           | 2 (4.9)            | 8 (11.3)  | 5 (4.3)            | 0.16    |
| Duration of symptoms, months | 2.6±1.4 | 2.4±1.1  | 2.6±1.5            | 0.44    |
| BCVA in logMAR         |                    |           |                    |         |
| Mean ± SD              | 0.52±0.34          | 0.49±0.38 | 0.61±0.37          | 0.08    |
| BCVA (Snellen equivalent) |                |           |                    |         |
| ≤20/200, n (%)         | 9 (22.0)           | 11 (15.5) | 28 (24.1)          | 0.37    |
| ≥20/40, n (%)          | 16 (39.0)          | 32 (45.1) | 32 (27.6)          | 0.04    |
| First branch, n (%)    | 19 (46.3)          | 38 (53.5) | 57 (49.1)          |         |
| Second branch, n (%)   | 22 (53.6)          | 33 (46.5) | 59 (50.9)          | 0.74    |
| No PVD, n (%)          | 24 (58.5)          | 51 (71.8) | 67 (57.8)          | 0.13    |
| Scatter photocoagulation, n (%) | 6 (14.6) | 4 (5.6)  | 13 (11.2)          | 0.27    |
| Foveal thickness       |                    |           |                    |         |
| Mean ± SD              | 554±201            | 538±176   | 556±206            | 0.83    |
| IOL at last visit, n (%)| 16 (39.0)          | 31 (43.7) | 116 (100)          |         |
| Follow-up duration, months |                |           |                    |         |
| Mean ± SD              | 57.0±35.7          | 53.8±36.9 | 56.0±36.9          | 0.89    |
| Range                  | 12–119             | 12–143    | 12–160             |         |

Abbreviations: logMAR, logarithm of minimum angle resolution; PVD, posterior vitreous detachment; BCVA, best corrected visual acuity; IOL, intraocular lens; tPA, tissue plasminogen activator.
Table 2 Summary of the BCVA and the foveal thickness

|                | Bevacizumab (n=41) | tPA (n=71) | Vitrectomy (n=116) | P-value |
|----------------|---------------------|------------|--------------------|---------|
| At 12 months   |                     |            |                    |         |
| BCVA (logMAR)  | Mean ± SD           | 0.20±0.34  | 0.18±0.31          | 0.21±0.34 | 0.80    |
| BCVA (Snellen equivalent) | VA≥20/40, n (%) | 29 (70.7) | 53 (74.6) | 89 (76.7) | 0.75    |
|                | VA≥20/20, n (%)     | 13 (31.7)  | 29 (40.8)          | 41 (35.3) | 0.59    |
| Degree of visual improvement, mean ± SD | 0.31±0.33 | 0.30±0.36 | 0.39±0.33 | 0.18    |
| Improved, n (%)| 29 (70.7)           | 46 (64.8)  | 81 (69.8)         | 0.18    |
| Unchanged, n (%)| 10 (24.4)        | 21 (29.6)  | 29 (25.0)        | 0.18    |
| Worsened, n (%)| 2 (4.9)             | 4 (5.6)    | 6 (5.2)           | 0.93    |
| Foveal thickness (μm) | Mean ± SD | 350±218   | 227±127           | 304±169 | 0.001   |
| At the final visit                                                                                   |
| BCVA (logMAR)  | Mean ± SD           | 0.19±0.32  | 0.15±0.32          | 0.16±0.36 | 0.83    |
| BCVA (Snellen equivalent) | VA≥20/40, n (%) | 32 (78.0) | 56 (78.9) | 96 (82.8) | 0.75    |
|                | VA≥20/20, n (%)     | 17 (41.5)  | 34 (47.9)          | 55 (47.4) | 0.59    |
| Degree of visual improvement, mean ± SD | 0.33±0.32 | 0.34±0.36 | 0.44±0.34 | 0.061   |
| Improved, n (%)| 27 (65.9)           | 48 (67.6)  | 87 (75.0)         | 0.061   |
| Unchanged, n (%)| 13 (31.7)           | 20 (28.2)  | 27 (23.3)        | 0.061   |
| Worsened, n (%)| 1 (2.4)             | 3 (4.2)    | 2 (1.7)           | 0.93    |
| Foveal thickness (μm) | Mean ± SD | 298±189   | 214±101           | 251±120 | 0.0045  |

Abbreviations: BCVA, best corrected visual acuity; logMAR, logarithm of minimum angle resolution; tPA, tissue plasminogen activator.

respectively). The mean foveal thickness in the tPA group was significantly thinner than that in the IVB group at the final visit (P=0.0047). There were no retinal tears, detachments, or infections resulting from the intravitreal injections.

The postoperative adverse events and the need for additional surgeries are shown in Tables 3 and 4. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. During the extended follow-up periods, two patients in the IVB group underwent vitrectomy for persistent macular edema, and one patient underwent vitrectomy for vitreous hemorrhage. In the tPA group, two patients underwent vitrectomy for persistent macular edema, and one patient underwent vitrectomy for vitreous hemorrhage. In the IVB group, two patients underwent vitrectomy for an epiretinal membrane, and one patient underwent vitrectomy for vitreous hemorrhage. Cataract surgery was performed when lens opacity progressed even slightly, and the rate of cataract surgery for phakic eyes at the final visit was 15/39 (38.5%) in the IVB group and 24/63 (38.1%) in

Table 3 Postoperative adverse events

|                | Bevacizumab (n=41) | tPA (n=71) | Vitrectomy (n=116) |
|----------------|---------------------|------------|--------------------|
| Epiiretinal membrane | 3                   | 8          | 0                  |
| Vitreous hemorrhage  | 2                   | 3          | 0                  |
| Glaucoma            | 1                   | 1          | 3                  |
| RRD                 | 0                   | 0          | 1                  |
| Foveal hard exudate | 1                   | 0          | 1                  |
| Subretinal fibrosis | 0                   | 1          | 1                  |
| Choroidal neovascularization | 0 | 0 | 1 |
| Descemet membrane folding | 0 | 1 | 0 |
| Fibrin membrane    | 0                   | 1          | 0                  |
| Subretinal hemorrhage | 0           | 1          | 0                  |
| Subcapsular cataract | 0                   | 1          | 0                  |
| Cerebral infarction | 0                   | 1          | 3                  |

Note: Data are expressed as number.

Abbreviations: RRD, rhegmatogenous retinal detachment; tPA, tissue plasminogen activator.
Table 4 Additional surgeries

|                      | Bevacizumab (n=41) | tPA (n=71) | Vitrectomy (n=116) |
|----------------------|--------------------|------------|--------------------|
| IOL                  | 5                  | 18         | 0                  |
| PPV                  | 3                  | 2          | 2                  |
| IOL+PPV              | 10                 | 6          | 0                  |
| Glaucoma surgery     | 1                  | 0          | 0                  |

Indication for vitrectomy

|                      |                    |            |                    |
|----------------------|--------------------|------------|--------------------|
| Persistent macular edema | 11                 | 2          | 0                  |
| Vitreous hemorrhage   | 2                  | 3          | 0                  |
| Epiretinal membrane   | 0                  | 3          | 0                  |
| Subretinal hard exudate | 0                  | 0          | 1                  |
| RRD                  | 0                  | 0          | 1                  |

Note: Data are expressed as number.
Abbreviations: IOL, intraocular lens; PPV, pars plana vitrectomy; RRD, rhegmatogenous retinal detachment; tPA, tissue plasminogen activator.

The BCVA between the three groups were not significant at all time points.

Figure 3 shows the time course of the difference in the foveal thickness for all groups. In all groups, the foveal thickness decreased postoperatively, and the changes in the foveal thickness from the baseline was significant at all time points (all, \(P<0.0001\)). A continuation of the decrease of the foveal thickness was observed in the tPA and vitreectomy groups during the extended follow-up period. An early decrease in the foveal thickness was observed in IVB group. The difference in the foveal thickness between 12 months and the final visit was statistically significant only in the vitrectomy group (\(P=0.0001\)). The mean foveal thickness in the IVB group was significantly thinner than that in the tPA and vitrectomy groups during the early postoperative period at 1 month (\(P=0.015\) and \(P=0.0018\), respectively) and at 2 months (\(P=0.039\) and \(P=0.007\), respectively).

Figure 2 Time course of the changes in the degree of visual improvement in logMAR for all groups.
Abbreviations: tPA, tissue plasminogen activator; logMAR, logarithm of minimum angle resolution; Vit, vitrectomy.

Figure 1 Time course of the changes in the BCVA for all groups. Continued visual improvement was observed in the tPA and vitreectomy groups. A rapid visual improvement was observed in the bevacizumab group.
Abbreviations: BCVA, best-corrected visual acuity; tPA, tissue plasminogen activator; logMAR, logarithm of minimum angle resolution; Vit, vitrectomy.
Table 5 presents the characteristics of the patients who underwent vitrectomy for persistent macular edema. Eleven patients were in the IVB group and two patients were in the tPA group. Of the 11 patients in the IVB group, nine patients refused to have additional IVB injections and two patients did not have any visual and anatomical improvement after the injection. The mean interval from the initial treatment to the vitrectomy was 15.8 months with a range of 13–30 months. The mean BCVA at the baseline was 0.50±0.36 logMAR units, at pre-vitrectomy was 0.45±0.37 logMAR units, and at the final visit was 0.17±0.18 logMAR units. The differences in the BCVAs between the final BCVA and baseline or pre-vitrectomy were significant ($p=0.0099$, $p=0.0062$, respectively).

The mean foveal thickness at the baseline was 541±103 μm, at pre-vitrectomy was 536±172 μm, and at the final visit was 277±82 μm. The differences between the thicknesses at the final visit and the baseline or pre-vitrectomy were significant ($p=0.0001$, $p=0.0002$, respectively).

The demographics and characteristics of the patients who underwent vitrectomy for postoperative complications are shown in Table 6. The mean interval from the initial treatment to the vitrectomy for a vitreous hemorrhage was 45.4 months with a range of 19–80 months. The mean interval from the initial treatment to vitrectomy for an epiretinal membrane was 61.0 months with a range of 20–133 months. The vitrectomy was successful in all of the eyes.

Figures 4 and 5 demonstrate the time course of the difference in the BCVA and the foveal thickness for the three types of the IVB group. There were no significant differences among the types in the baseline BCVA and foveal thickness. There were no significant differences in the BCVA and the foveal thickness at all time points between the good response type and the vitrectomized type.

**Discussion**

The results showed that the BCVA was significantly improved at the end of the first year after the initial treatment in the three groups, and the BCVA was maintained for about 40 months thereafter. The differences in the BCVA between the three groups were not significant at all time points. However, 39.0% of patients in the IVB group, 33.8% in the tPA group, and 1.7% of patients in the vitrectomy group had to undergo additional surgeries during the follow-up period. Our findings indicate that the vitrectomy group had less chance of needing additional surgery but had comparable long-term visual results as the other two groups.

The time course of the changes in the BCVA and foveal thickness showed continued improvements in the tPA and...
Table 6  Summaries of patients who underwent vitrectomy for complications

| Case | Age, year | Initial treatment | Lens | Complication | Surgery | Months from initial treatment | VA in decimal | Follow-up, months |
|------|-----------|-------------------|------|--------------|---------|-------------------------------|---------------|------------------|
| 1    | 52        | IVB 1 time        | Phakic | VH | Triple | 30 | 0.50 | 1.50 | 1.50 | 92  |
| 2    | 59        | IVB 3 times       | Phakic | VH | Triple | 53 | 0.30 | 0.80 | 0.60 | 54  |
| 3    | 72        | tPA               | Phakic | VH | Triple | 80 | 0.70 | 0.30 | 1.00 | 90  |
| 4    | 49        | tPA               | Phakic | VH | Triple | 45 | 0.20 | 0.30 | 0.50 | 132 |
| 5    | 82        | tPA               | Phakic | VH | Triple | 19 | 0.30 | 0.80 | 1.00 | 44  |
| 6    | 61        | tPA               | Phakic | ERM | PPV* | 20 | 0.40 | 0.70 | 0.90 | 30  |
| 7    | 76        | tPA               | Phakic | ERM | PPV** | 30 | 0.03 | 0.30 | 0.40 | 47  |
| 8    | 65        | tPA               | Phakic | ERM | PPV | 133 | 0.70 | 0.60 | 0.70 | 143 |
| 9    | 59        | Vit               | Phakic | RRD | PPV | 2 | 0.10 | 0.15 | 0.20 | 68  |
| 10   | 55        | Vit               | Phakic | Subretinal HE | PPV | 17 | 0.50 | 0.30 | 1.20 | 97  |

**Abbreviations:** VH, vitreous hemorrhage; IVB, intravitreal bevacizumab; ERM, epiretinal membrane; RRD, rhegmatogenous retinal detachment; HE, hard exudate; Triple, vitrectomy with cataract surgery; PPV, pars plana vitrectomy; Vit, vitrectomy; PPV*, cataract surgery at 16 months after first treatment; PPV**, cataract surgery at 13 months after first treatment; VA, visual acuity; tPA, tissue plasminogen activator.

Vitrectomy groups and rapid and sustained improvements in the IVB group. The mean foveal thickness was significantly thinner in the IVB group than in the tPA and vitrectomy groups during the early postoperative period. The mean BCVA in the good response type of the IVB group was significantly better than that in the vitrectomy group at 2 months ($P = 0.040$). A retrospective analysis in the BRAVO and CRUISE trials showed that more than 50% of the patients treated with monthly intravitreal ranibizumab (IVR) injections achieved clinically significant improvements in their vision during the initial 6 months after the IVR.$^{40}$ The rapid and sustained improvements are advantages for the IVB injections and are also present with the other anti-VEGF agents. These findings indicate that IVB injections lead to rapid anatomical and functional improvements compared with the other groups.

Another advantage of IVB is its lower cost. The 2015 Medicare reimbursement for anti-VEGF therapy for macular edema due to BRVO is $1,967 for ranibizumab, $1,961 for aflibercept, and $17 for bevacizumab. In addition, off-label repackaged bevacizumab and other anti-VEGF drugs such as aflibercept and ranibizumab are reported to be similarly effective in the treatment of patients with RVO.$^{1,7,8,41–43}$ and diabetic macular edema.$^{7,44}$

Additional surgeries in the IVB and tPA groups included cataract surgery and vitrectomy for persistent macular edema, epiretinal membrane, and vitreous hemorrhage. The remaining phakic patients have the possibility of cataract surgery in the future. Not only the treatment but also aging is one of the causes for the cataract. Vitrectomy for epiretinal membrane was performed in three eyes of the tPA group at 20, 30, and 133 months after the initial tPA injection. Vitrectomy for vitreous hemorrhage was performed in two eyes in the IVB group at 30 and 53 months and in three eyes in the tPA group at 19, 45, and 80 months after the initial tPA injection.
Epiretinal membranes and vitreous hemorrhages are possibly associated with the abnormal vitreoretinal interface after IVB or intravitreal tPA injections. These findings indicated that further surgeries will possibly be needed after a long time after the IVB or intravitreal tPA injection perhaps even after other intravitreal injections.

Eleven eyes underwent vitrectomy for a recurrence or persistent macular edema in the IVB group, and they all had similar final BCVA with good responses. It is possible that other treatments such as an initial three IVB, another anti-VEGF agent, or a combination of other treatments might obtain more favorable outcomes. However, our findings indicated that vitrectomy is a good optional treatment for persistent macular edema. Some authors have also reported that vitrectomy was effective for recurrent or persistent macular edema. 3,4,11,12

The results showed that the vitrectomy group achieved visual outcomes comparable to IVB and tPA groups with fewer additional surgeries. Vitrectomy was reported to be a useful method in terms of the relative costs and benefits for diabetic macular edema and proliferative diabetic retinopathy. 10 In addition, vitrectomy is an invasive procedure but has become a safer treatment option with the development of new technology, such as small-gauge instruments, wide-angle viewing systems, and safer dyes used for making the vitreous and membranes more visible. We believe that vitrectomy might be one of effective treatments for macular edema due to BRVO.

There are limitations in this study. First, this study was not a randomized study with a control group. Second, the effects of other anti-VEGF agents were not determined. Third, IVB might be under-treated. Fourth, the baseline VA was not equally distributed. The positive aspects of this study include a relatively large sample size, longer follow-up period, and the use of BCVA. In addition, all eyes except the clear phakic eyes were pseudophakic at the last visit so a worsening of nuclear sclerotic cataracts did not influence the final BCVA.

In conclusion, the BCVA and foveal thickness improve in the vitrectomy group as compared to IVB and tPA groups with fewer additional surgeries. Vitrectomy was reported to be a useful method in terms of the relative costs and benefits for diabetic macular edema and proliferative diabetic retinopathy. In addition, vitrectomy is an invasive procedure but has become a safer treatment option with the development of new technology, such as small-gauge instruments, wide-angle viewing systems, and safer dyes used for making the vitreous and membranes more visible. We believe that vitrectomy might be one of effective treatments for macular edema due to BRVO.

The authors report no conflicts of interest in this work.

**References**

1. Ehlers JP, Kim SJ, Yeh S, et al. Therapies for macular edema associated with branch retinal vein occlusion: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2017;124(9):1412–1423. doi:10.1016/j.ophtha.2017.03.060

2. Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. *J Ophthalmol*. 2017;2017:4936924.

3. Esmaili DD, Boyer DS. Recent advances in understanding and managing retinal vein occlusions. *F1000Res*. 2018;16(7):467. doi:10.12688/f1000research.12886.1

4. Smiddy WE. Economic considerations of macular edema therapies. *Ophthalmology*. 2011;118:1827–1833. doi:10.1016/j.ophtha.2010.12.034

5. Erie JC, Barkmeier AJ, Hodge DO, Mahr MA. High variation of intravitreal injection rates and Medicare anti-vascular endothelial growth factor payments per injection in the United States. *Ophthalmology*. 2016;123:1257–1262. doi:10.1016/j.ophtha.2016.02.015

6. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Diabetic retinopathy clinical research network. cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. *JAMA Ophthalmol*. 2016;134(8):888–896. doi:10.1001/jamaophthalmol.2016.1669

7. Low A, Kangsagara D, Freeman M, et al. Comparative clinical and economic effectiveness of anti-vascular endothelial growth factor agents [Internet]. VA Evidence-based Synthesis Program Reports. Washington (DC): Department of Veterans Affairs (US); 2017 Jan.

8. Scott IU, VanVeldhuisen PC, Ip MS, et al. SCORE2 investigator group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. *JAMA*. 2017;317(20):2072–2087. doi:10.1001/jama.2017.4568

9. Wu AM, Wu CM, Greenberg PB, Yu F, Lum F, Coleman AL. The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries. *Am J Ophthalmol Case Rep*. 2018;11:105–108. doi:10.1016/j.ajocare.2018.06.005

10. Lin J, Chang JS, Yannuzzi NA, Smiddy WE. Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy. *Ophthalmology*. 2018;pii:S0161-6420(18)30040-X.

11. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. *Br J Ophthalmol*. 2009;93(4):452–456. doi:10.1136/bjo.2008.141085

12. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. *Retina*. 2009;29(4):511–515. doi:10.1097/IAE.0b013e318195ca65

13. Gregori NZ, Rattan GH, Rosenfeld PJ, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. *Retina*. 2009;29(7):913–925. doi:10.1097/IAE.0b013e3181aa8de

14. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. *Retina*. 2009;29(9):1242–1248. doi:10.1097/IAE.0b013e3181a8e20
71. Mandelcorn MS, Nrusimhadevara RK. Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. *Retina*. 2004;24(3):348–355.

30. Mandelcorn MS, Nrusimhadevara RK. Internal limiting membrane peeling for decompression of macular edema as primary treatment for macular edema secondary to branch retinal vein occlusion. *Ophthalmology*. 2004;111(3):540–545. doi:10.1016/j.opth.2003.05.032

29. Charbonnel J, Glacet-Bernard A, Korobelnik JF, et al. Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. *Graefes Arch Clin Exp Ophthalmol*. 2004;242(3):223–228. doi:10.1007/s00417-003-0982-4

28. Udaondo P, Díaz-Llopis M, García-Delpech S, Salom D, Romero FJ. Three treatments for macular edema due to branch retinal vein occlusion: intravitreous bevacizumab or tissue plasminogen activator, and vitrectomy. *Retina*. 2012;32(3):520–529. doi:10.1097/IAE.0b013e31822529c2

27. Shah GK, Sharma S, Fineman MS, et al. Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion. *Int J Ophthalmol*. 2010;4(6):294.

26. Tachi N, Hasimoto Y, Ogino N. Retinectomy for decompression of macular edema due to retinal vein occlusion. *Jpn J Ophthalmol*. 2012;41(7):294.

25. Thach AB, Yau L, Huang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. *Ophthalmology*. 2014;121(5):1059–1066. doi:10.1016/j.opth.2013.11.022

24. Yuan A, Ahmad BU, Xu D, et al. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion after antivascular endothelial growth factor treatments. *Clin Ophthalmol*. 2016;10:277–283. doi:10.2147/OPHT.S85751

23. Sakuma T, Mizota A, Inoue J, Tanaka M. Intravitreal injection of autologous plasmid enzyme for macular edema associated with branch retinal vein occlusion. *Am J Ophthalmol*. 2010;150(6):876–882. doi:10.1016/j.ajo.2009.06.005

22. Tagami M, Kusuhara S, Imai H, Honda S, Tsukahara Y, Negi A. Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion. *Ophthalmologica*. 2011;226(2):81–86. doi:10.1159/000326242

21. Udaondo P, Díaz-Llopis M, García-Delpech S, Salom D, Romero FJ. Intravitreal plasmid without vitrectomy for macular edema secondary to branch retinal vein occlusion. *Arch Ophthalmol*. 2011;129(3):283–287. doi:10.1001/archophthalmol.2011.8

20. Tagami M, Kusuhara S, Imai H, Honda S, Tsukahara Y, Negi A. Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion. *Ophthalmologica*. 2011;226(2):81–86. doi:10.1159/000326242

19. Ach T, Hoeh AE, Schaal KB, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy for retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol*. 2010;248(2):155–159. doi:10.1007/s00417-009-1167-6

18. Kriechbaum K, Prager F, Geitzenauer W, et al. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. *Ophthalmology*. 2009;116(12):2415–2421. doi:10.1016/j.opth.2009.05.001

17. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. *Doc Ophthalmol*. 2004;109(3):348–355.

16. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Long-term follow-up of OCT-guided treatment of macular edema due to retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol*. 2009;247(12):1635–1641. doi:10.1007/s00417-009-1151-1

15. Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American collaborative retina study group at 24 months. *Retina*. 2009;29(10):1396–1403. doi:10.1097/IAE.0b013e3181beccef53
Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal